FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer
The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Adding Checkpoint Inhibition in Trastuzumab-Resistant HER2+ Breast Cancer
An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1 –positive, trastuzumab-resistant, advanced HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 4, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Subcutaneous Herceptin OK'd for Breast Cancer
(MedPage Today) -- Study found 86% of patients preferred it to IV formulation (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 28, 2019 Category: OBGYN Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Media News)
Source: Roche Media News - February 28, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - February 28, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers
South San Francisco, CA -- February 28, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2019 Category: Drugs & Pharmacology Source Type: news

NHS prescription charge to rise to £9
20p rise on single prescription fee Related items fromOnMedica NICE rejects breast cancer drug for NHS funding Wales cancer spend at record high JCVI recommends universal HPV vaccination Promise to end new HIV transmissions in England by 2030 NICE recommends Herceptin for gastric cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 21, 2019 Category: UK Health Source Type: news

Can Trastuzumab Therapy Continue After LVEF Decline in HER2+ Breast Cancer?
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of< 50%. (Source: CancerNetwork)
Source: CancerNetwork - February 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Trastuzumab Biosimilar Proves Mettle in Two Breast Ca Trials (CME/CE)
(MedPage Today) -- Pfizer ' s biosimilar efficacious and safe for first-line treatment as a branded trastuzumab (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 8, 2019 Category: Hematology Source Type: news

Breast cancer cells shifted into HER2 positive status with bold new strategy
(Scripps Research Institute) One of the most effective breast cancer drugs, Herceptin, is only available to people whose tumors test HER2-positive. That's only one in five breast cancer patients. That could change with a new approach from Scripps Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2019 Category: Cancer & Oncology Source Type: news

MacroGenics stock spikes from positive results of cancer drug trial
Rockville-based MacroGenics Inc. announced positive results Wednesday from late-stage trials of its breast cancer therapy candidate, sending the company ’s stock price soaring nearly 200 percent for the day. The biotech’s margetuximab product — which targets the “HER2” gene, which can feed the growth of cancer cells, specifically in patients with metastatic breast cancer — was found to be safer and better tolerated than Genentech Inc.'s Herceptin, considered a standard treatment today,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 6, 2019 Category: Health Management Authors: Sara Gilgore Source Type: news

MacroGenics stock spikes from positive results of cancer drug trial
Rockville-based MacroGenics Inc. announced positive results Wednesday from late-stage trials of its breast cancer therapy candidate, sending the company ’s stock price soaring nearly 200 percent for the day. The biotech’s margetuximab product — which targets the “HER2” gene, which can feed the growth of cancer cells, specifically in patients with metastatic breast cancer — was found to be safer and better tolerated than Genentech Inc.'s Herceptin, considered a standard treatment today,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2019 Category: Biotechnology Authors: Sara Gilgore Source Type: news

UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future research — which Slamo...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Roche adapts newer breast cancer drug in face of Herceptin imitations
Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche moves to broaden Kadcyla use in biosimilar defense
Roche aims to broaden use of its Kadcyla breast cancer drug as the Swiss pharmaceuticals giant defends itself against rivals who are crowding in with cheaper biosimilar copies of its older, patent-expired mainstay Herceptin. (Source: Reuters: Health)
Source: Reuters: Health - February 5, 2019 Category: Consumer Health News Tags: healthNews Source Type: news